1. Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction
- Author
-
Amir H. Mohammadpour, Mashalla Dehghani, Maryam Vahabzadeh, Mohsen Moohebati, Homa Falsoleiman, Bizhan Malaekeh-Nikouie, Amir Farjam Fazelifar, Ali Gholamzadeh, Sara Amini, Afsoon Fazlinezhad, and Mostafa Dastani
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Myocardial Infarction ,Hemodynamics ,Pilot Projects ,Iran ,arrhythmia ,Sudden death ,Electrocardiography ,Percutaneous Coronary Intervention ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Creatine Kinase, MB Form ,Humans ,Myocardial infarction ,cardiovascular diseases ,Pharmacology ,medicine.diagnostic_test ,business.industry ,food and beverages ,Percutaneous coronary intervention ,Arrhythmias, Cardiac ,Middle Aged ,medicine.disease ,Recombinant Proteins ,Treatment Outcome ,Erythropoietin ,Conventional PCI ,cardiovascular system ,Cardiology ,Platelet aggregation inhibitor ,Original Article ,Female ,erythropoietin ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,Biomarkers ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Background: Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. Methods: We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI. Results: A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI. Conclusion: High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.
- Published
- 2015